Tracers / [131I]PSMA-769-d-tyrosine

[131I]PSMA-769-d-tyrosine

Also written as [I-131]PSMA-769-d-tyrosine

Radionuclide: I-131 t½ 11549 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: PSMA-targeted Glu-ureido (Lys-urea-Glu) small-molecule inhibitor with Gly-D-Tyr brush border enzyme-cleavable linker
Target / mechanism: Prostate-specific membrane antigen (PSMA) inhibitor PMID 29803076
Clinical application: —
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC+SPE	45.5 ± 8.5%	>99%	tin precursor d-11	29803076 2018 Nucl Med Biol Radioiodinated PSMA-769-d-tyrosine was synthesized similarly from the corresponding tin precursor d-11 — Radioiodinated PSMA-769-d-tyrosine was synthesized similarly from the corresponding tin precursor d-11 in 45.5 ± 8.5% (n = 2) and radiochemical purity of >99%.

Need this precursor?We can point you to suppliers for [131I]PSMA-769-d-tyrosine, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 29803076. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29803076: 'tin precursor d-11'.